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A Mutation (2314delG) in the Usher Syndrome Type
IIA Gene: High Prevalence and Phenotypic Variation
To the Editor:
Usher syndrome (USH), an autosomal recessive condi-
tion, is characterized by hearing impairment associated
with retinitis pigmentosa (RP). It is a clinically and ge-
netically heterogeneous condition. Three clinical forms
of USH have been described, and eight loci have been
mapped (Hereditary Hearing Loss home page). USH
type I (USH1) is the most severe form, manifested by
profound congenital deafness, constant vestibular dys-
function, and prepubertal onset of RP. USH type II
(USH2) is characterized by congenital moderate-to-se-
vere hearing impairment, normal vestibular responses,
and RP (Smith et al. 1994). USH type III (USH3) is
characterized by progressive hearing loss, variable ves-
tibular problems, and RP (Pakarinen et al. 1995). The
USH1B gene has been identified (Weil et al. 1995), and
a variety of mutations leading to USH1 have been cat-
alogued in the MYO7A gene (Liu et al. 1998). USH2 is
the most common of the three types of USH, accounting
for more than half of all cases (Hopes et al. 1997; Ro-
senberg et al. 1997).
Recently, Eudy et al. (1998) reported the identification
of the USH type IIA gene (USH2A; MIM 276901).
USH2A encodes a putative extracellular matrix protein
of 1,551 amino acids with laminin epidermal growth
factor and fibronectin type II motifs. Expression of the
USH2A gene has been detected by reverse transcriptase
PCR (RT-PCR) from fetal human cochlea, eye, and adult
human retina (Eudy et al. 1998). Three different mu-
tations were identified in patients with USH2A, the most
frequent of which is the 2314delG mutation. Of 96 pro-
bands tested, 21 carried the 2314delG mutation.
In the present study, we have undertaken mutational
analysis of the USH2A gene in 23 families with USH
(both USH2 and atypical USH), from the United King-
dom and China. We found that the majority of families
with USH2 carry the 2314delG mutation. Surprisingly,
we determined that the 2314delG mutation in the
USH2A gene can also lead to atypical USH.
Of 23 families with USH analyzed in this study, 15
have been described elsewhere (Hopes et al. 1997). All
available affected subjects were examined by one of the
authors. Full clinical histories were obtained, with em-
phasis on any potential causes of hearing impairment.
The audiovestibular and ophthalmic evaluations were
done on the basis of recommendations by the Usher
Syndrome Consortium (Smith et al. 1994). The details
of the clinical evaluations can be found in Hopes et al.
(1997). The cases studied here are classified clinically
into the following two groups: (1) USH2, consisting of
congenital sloping moderate/severe hearing impairment,
normal vestibular function, and RP (Smith et al. 1994);
and (2) atypical USH, consisting of bilateral sensorineu-
ral progressive hearing loss without other obvious fac-
tors as the cause of the progression of the hearing im-
pairment, along with variable vestibular dysfunction and
RP.
Of 23 families studied, 13 were given a diagnosis of
USH2 and 10 were given a diagnosis of atypical USH.
Eighteen families living in the United Kingdom and five
in China were included in our analyses. Twenty-three
probands with USH were screened for the 2314delG
mutation by combined SSCP/heteroduplex analysis.
Twelve families (52%) carried the 2314delGmutation—
8 (62%) of 13 patients with typical USH2 and 4 (40%)
of 10 patients with atypical USH (table 1). Of 12 families
with this mutation, 7 were identified with only one af-
fected member (sporadic cases). Of the remaining five
families with more than one affected individual, two
families (USH.05 and USH.10) with two affected sibs
were tested for cosegregation of the disease with the
USH2A locus (Eudy et al. 1998). The segregation anal-
ysis was consistent with linkage to USH2A (data not
1222 Letters to the Editor
Table 1
Summary of 2314delG Mutations Identified in the USH2A Gene








USH.01 UK Homozygous 2 Atypical
USH.02 UK Homozygous 2 II
USH.03 UK Heterozygous 1 II
USH.04 UK Heterozygous 1 II
USH.05 UK Homozygous 4 Atypical
USH.06 UK Heterozygous 1 II
USH.07 UK Heterozygous 1 II
USH.08 UK Heterozygous 1 Atypical
USH.09 China Homozygous 2 Atypical
USH.10 UK Heterozygous 2 II
USH.11 China Heterozygous 1 II
USH.12 UK Heterozygous 1 II
USH.13 China None 0 II
USH.14 China None 0 II
USH.15 UK None 0 II
USH.16 UK None 0 II
USH.17 UK None 0 II
USH.18 China None 0 Atypical
USH.19 UK None 0 Atypical
USH.20 UK None 0 Atypical
USH.21 UK None 0 Atypical
USH.22 UK None 0 Atypical
USH.23 UK None 0 Atypical
a UK  United Kingdom.
shown). Examination of genotypes for markers
AFM143XF10, AFM268D1, and AFM144XF2 reveal
that all patients with the 2314delG mutation do not
share the same genotype for the three markers (data not
shown).
Four affected children from three families from the
United Kingdom (USH.01, USH.02, and USH.05) were
identified to be homozygous for the 2314delGmutation,
as well as one affected child from the Chinese family
USH.09 (table 1). In addition, eight affected individuals
from seven other U.K. families, as well as one additional
family from China, were found to be heterozygous for
this mutation (table 1). To exclude the possibility that
the 2314delG mutation is simply a common polymor-
phism in the populations we studied, we analyzed 80
unrelated control samples (40 from the United Kingdom
and 40 from China) for this mutation. No mutation was
detected from this panel of control DNA samples.
Of 12 families with the 2314delG mutation, 8 families
had the typical USH2 phenotype—congenital moderate-
to-severe hearing impairment, normal vestibular func-
tion, and postpubertal onset of RP. However, five af-
fected individuals from the remaining four families
carrying the 2314delG mutation showed atypical USH
features, with progressive hearing impairment, variable
vestibular function, and RP (table 2). Two patients from
an atypical USH family (USH.05) were identical twins
with nonconsanguineous parents. The index twin (age
49 years) had worn hearing aids from age 14 years and
remembered hearing well until age ∼10 years. He be-
lieved his hearing loss had progressed since that time.
His last audiogram confirmed that his hearing loss had
progressed from moderate to severe. He had normal ves-
tibular function. He had suffered from night blindness
since early childhood and loss of visual field since age
∼20 years. The electroretinogram was extinguished and
his fundi showed typical pigmentary degeneration with
bone spicule pigmentation. His twin brother had been
given a diagnosis of hearing loss and had worn hearing
aids at age 8 years. He did not feel that his hearing loss
had progressed, but there were negative caloric re-
sponses. RP was given as a diagnosis at age 40 years,
but he was symptomatic in childhood. These data in-
dicate phenotypic variation between monozygotic twins.
The isolated patient (age 39 years) from the second atyp-
ical family (USH.01) was typical of USH2 in all aspects,
including nonprogressive hearing loss, but had absent
vestibular function, which is a critical discriminator in
clinical classification. Further details of clinical evalua-
tion for both families have been reported by Hopes et
al. (1997).
In family USH.09, originating fromChina, the parents
were unrelated and unaffected. The patient (age 38
years) had been determined to have bilateral hearing loss
at age 10 years. There are no other affected individuals
in her family. She believed her hearing had deteriorated.
Comparison with one available audiogram 7 years pre-
viously showed progression of hearing loss from 45 de-
cibel-hearing level (dB HL) to 75 dB HL, across all fre-
quencies. She had normal vestibular function. Night
blindness was present from age 14 years, and RP was
given as a diagnosis at age 21 years.
The patient from USH.08 is a 38-year-old woman
from the United Kingdom with nonconsanguineous par-
ents. She had been given a diagnosis of hearing loss at
age 5 years. Her hearing loss had progressed to the pre-
sent average of 53 dB HL (down-sloping audiogram)
from 38 dB HL 10 years ago. She has normal speech
and normal vestibular function. Her RP was formally
confirmed at age 35 years, but she was symptomatic
from age 26 years.
The mutations described here, particularly the occur-
rence of a frequent 2314delG mutation in familial and
sporadic USH families, support the recent observation
that the USH2A gene is responsible for USH2 (Eudy et
al. 1998). Eudy and colleagues found three frameshift
mutations, including 2314delG, 2913delG, and 4353-
54delCT, in the USH2A gene. The 4353-54delCT mu-
tation was found in a heterozygous patient with USH2A
in the Louisiana Acadian population. Eudy et al. (1998)
found that one of the mutations, 2314delG, occurred at
a high frequency (22%) in 96 probands. Most patients
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Table 2



















1 6 years Sloping, mod/sev - 21 10 Moderate
USH.02:
1 6 years Sloping, mod/sev  17 17 Moderate
USH.03:
1 15 mo Sloping, mod/sev  30 20 Moderate
USH.04:
1 Infant Sloping, mod/sev  58 54 Moderate
USH.05:
1 14 years Progressive sloping, mod/sev  40 10 Moderate
1 8 years Sloping, mod/sev  40 10 Moderate
USH.06:
1 18 mo Sloping, mod/sev  35 32 Moderate
USH.07:
1 2 years Profound  17 15 Moderate
USH.08:
1 5 years Progressive sloping, mod/sev  35 26 Mild
USH.09:
1 10 years Progressive mod/sev  21 14 Moderate
USH.10:
1 5 years Sloping, mod/sev  14 22 Moderate
1 2 years Sloping, mod/sev  Unknown 20 Mild
USH.11:
1 3 years Sloping, mod/sev  22 18 Moderate
USH.12:
1 2 years Sloping, mod/sev  43 43 Mild
a “Sloping” denotes worse thresholds in the high frequencies; “mod/sev” denotes moderate to severe hearing impairment.
b A plus sign () indicates normal; a minus sign () indicates abnormal.
with the 2314delG mutation had northern European an-
cestry, but two homozygous patients were of Spanish or
African origin. In the present study, we have also found
that the 2314delG mutation is particularly frequent in
patients with typical USH2. We found this mutation in
62% of our patients with USH2. The mutation
2314delG lies within a crucial region in the laminin ep-
idermal growth factor motif of USH2A and results in a
frameshift at codon 772 and a premature stop codon
20 amino acids downstream, presumably leading to a
truncated protein and loss of function. It seems likely
that those patients who are heterozygous for this mu-
tation are compound heterozygotes, and identification
of the other mutant alleles remains to be done. Until the
entire USH2A gene has been screened for mutations, the
relative frequency of this particular mutation cannot be
accurately assessed. The families we have studied car-
rying this frequent mutation originate from the United
Kingdom and China. The identification of the 2314delG
mutation in four widely dispersed populations (northern
Europe, Spain, Africa, and China) suggests that a foun-
der effect was not involved in propagating the mutation.
Rather, the 2314delG mutation may represent a muta-
tional hot spot within the USH2A gene. Haplotype anal-
ysis of 2314delG in different populations could be used
to address this question definitively.
The existence of two forms of USH—USH1 and
USH2—has achieved a general acceptance among cli-
nicians in the past two decades. Both types can be dis-
tinguished by the severity and the presence of vestibular
dysfunction. A third group of patients that present with
progressive hearing loss and variable vestibular prob-
lems along with RP. Patients in this class have been de-
scribed as affected with “USH3” (Pakarinen et al. 1995),
although some families, in the absence of any clear ge-
netic distinction with other USH classes, may be best
classified as having an atypical USH phenotype. How-
ever, USH3, as a clinical entity distinct from USH2, has
been accepted only recently, on the basis of a genetic
linkage analysis of Finnish families that demonstrated
linkage to a locus on 3q not previously implicated in
either USH1 or USH2 (Sankila et al. 1995).
In the present study, all but four of families with a
2314delG mutation showed typical clinical character-
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istics of USH2, as determined by clinical criteria (Smith
et al. 1994). The phenotypic features in the families
USH.05, USH.08, and USH.09 are quite similar to the
Finnish USH3 families (Sankila et al. 1995). Mutational
analysis of four families with atypical USH demon-
strated that four affected individuals are homozygous
and one is heterozygous for the 2314delG mutation in
the USH2A gene (table 1). This indicates that mutations
in the USH2A gene can give rise to atypical USH, as
well as to USH2.
The phenotypic variation observed in individuals with
the 2314delG mutation suggests that environmental or
genetic factors affect expression of USH2A. The same
mutation is expected to be associated with a uniform
clinical picture, but there are many instances in which
identical mutations in a gene can result in phenotypic
variation (Romeo and McKusick 1994; Wolf 1997). Ge-
netic factors that could account for the phenotypic var-
iability could include effects of the genetic background,
including modifier genes, and even additional mutations
in the USH2A gene modifying the phenotype. Our ob-
servations on the disconcordant phenotype of the mon-
ozygotic twins carrying the same mutation suggest that
variation in the expression of the USH2A gene is not
determined simply by genetic factors (i.e., modifier
genes). We have shown that different mutations in
MYO7A can lead to a wide range of phenotypes, in-
cluding USH type IB, autosomal recessive nonsyndromic
deafness, and autosomal dominant nonsyndromic deaf-
ness (Liu et al. 1997a, 1997b). Recently, we reported
that mutations in the MYO7A gene can also lead to
atypical USH (Liu et al. 1998). Including the present
data, we have shown that atypical USH and USH3 are
apparently genetically heterogeneous, with mutations at
different loci on 3q, 11q, and 1q in different families.
Most important, it is also clear that the same mutation
at the USH2A locus can give rise to USH2 as well as to
atypical USH. Overall, the present data underline both
the genetic and phenotypic heterogeneity that is ob-
served in USH and the difficulties that will face us in
using molecular criteria for diagnosis and management.
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Different Functional Outcome of RetGC1 and RPE65
Gene Mutations in Leber Congenital Amaurosis
To the Editor:
Leber congenital amaurosis (LCA) has the earliest age
at onset and is the most severe of the inherited retinal
dystrophies (Leber 1869). It accounts for 5% of all
retinal dystrophies and probably accounts for a higher
percentage in countries with a high rate of consanguinity
(Foxman et al. 1985; Kaplan et al. 1990). LCA is an
autosomal recessive condition, distinct from all other
retinopathies in that the visual disorder is diagnosed at
birth or during the first months of life in an infant with
total blindness or greatly impaired vision, normal fun-
dus, and extinguished electroretinogram (ERG; Fran-
ceschetti and Dieterle 1954). Although major visual im-
pairment is easily recognizable at birth, LCA was largely
underdiagnosed until ERG performed on infants showed
that the condition is not uncommon. A certain degree
of clinical heterogeneity has long been recognized in
LCA (Merin 1991; Trabousli et al. 1995); however, ge-
netic heterogeneity of LCA has been suspected since the
report by Waardenburg et al. (1963) of normal-sighted
children born to parents who were both affected with
LCA.
We mapped the first LCA gene (LCA1) on the short
arm of chromosome 17p13.1 and confirmed the genetic
heterogeneity of the disease (Camuzat et al. 1995, 1996).
Perrault et al. (1996) ascribed LCA1 to mutations in the
photoreceptor-specific guanylate cyclase gene, RetGC1,
which catalyses the conversion of guanine triphosphate
to cyclic guanine monophosphate (cGMP) in the retina.
To date, a total of 18 different mutations have been
found in 20 unrelated families originating from various
countries across the world, especially the Mediterranean
region. The observation of missense and frameshift
RetGC1 mutations suggests that the cGMP production
in photoreceptor cells is markedly reduced or abolished
in LCA (Perrault et al. 1996). As a consequence, the
excitation process of rod and cone photoreceptorswould
be markedly impaired because of constant closure of
cGMP-gated cation channels, with hyperpolarization of
